文献速递骨质疏松与钙磷/甲状旁腺肥胖与代谢综合征

D-健康试验:维生素D对死亡率影响的随机对照试验

The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-01-10

在澳大利亚60岁及以上未筛查人群中开展随机双盲安慰剂对照试验,每月口服60000 IU维生素D3或安慰剂5年。共随机分配21315人,中位随访5.7年。维生素D3未降低全因死亡率(HR 1.04,95%CI 0.93-1.18;P=0.47);探索性分析排除随访前2年,维生素D组癌症死亡风险数值上更高(HR 1.24,95%CI 1.01-1.54;P=0.05)。

要点

  • 每月60000 IU维生素D3未降低60岁及以上未筛查澳洲成人的全因死亡率。
  • 心血管病死亡率HR 0.96(95%CI 0.72-1.28),癌症死亡率HR 1.15(95%CI 0.96-1.39)。
  • 排除前2年随访的探索性分析中,维生素D组癌症死亡HR 1.24(95%CI 1.01-1.54)。

核心结论

  • 每月补充维生素D3未降低未筛查老年人的全因死亡率。
  • 点估计及排除早期随访的探索性分析结果与癌症死亡风险增加相符。
  • 作者表示,在进一步证据出现前,预防原则提示该给药方案可能不适用于维生素D充足者。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在澳大利亚通过联邦选举名册全国招募60岁及以上成人。
  • 参与者按1:1随机分配至每月口服60000 IU维生素D3或安慰剂,持续5年。
  • 共随机分配21315人(维生素D组10662人,安慰剂组10653人);主要分析纳入维生素D组10661人和安慰剂组10649人。

主要发现

  • 随访期间采集的4441份血样(来自3943名随机抽样参与者)显示,安慰剂组平均血清25-羟基维生素D浓度为77(SD 25)nmol/L,维生素D组为115(SD 30)nmol/L。
  • 5年干预后(中位随访5.7年,IQR 5.4-6.7)共记录1100例死亡:安慰剂组538例(5.1%),维生素D组562例(5.3%)。
  • 维生素D3对全因死亡率的HR为1.04(95%CI 0.93-1.18;P=0.47)。
  • 维生素D3对心血管病死亡率的HR为0.96(95%CI 0.72-1.28;P=0.77);癌症死亡率HR为1.15(95%CI 0.96-1.39;P=0.13);其他原因死亡率HR为0.83(95%CI 0.65-1.07;P=0.15)。
  • 符合方案分析的OR为1.18(95%CI 1.00-1.40;P=0.06);排除前2年随访的探索性分析中,维生素D组癌症死亡风险数值上高于安慰剂组(HR 1.24,95%CI 1.01-1.54;P=0.05)。

临床怎么用

  • 作者认为,在进一步证据出现前,预防原则提示每月60000 IU维生素D3方案可能不适用于维生素D充足者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of supplementing unscreened adults with vitamin D3 on mortality is unclear. We aimed to determine whether monthly doses of vitamin D3 influenced mortality in older Australians. METHODS: We did a randomised, double-blind, placebo-controlled trial of oral vitamin D3 supplementation (60 000 IU per month) in Australians 60 years or older who were recruited across the country via the Commonwealth electoral roll. Participants were randomly assigned (1:1), using automated computer-generated permuted block randomisation, to receive one oral gel capsule of either 60 000 IU vitamin D3 or placebo once a month for 5 years. Participants, staff, and investigators were blinded to study group allocation. The primary endpoint was all-cause mortality assessed in all participants who were randomly assigned. We also analysed mortality from cancer, cardiovascular disease, and other causes. Hazard ratios (HRs) and 95% CIs were generated using flexible parametric survival models. This trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12613000743763. FINDINGS: Between Feb 14, 2014, and June 17, 2015, we randomly assigned 21 315 participants, including 10 662 to the vitamin D group and 10 653 to the placebo group. In 4441 blood samples collected from randomly sampled participants (N=3943) during follow-up, mean serum 25-hydroxy-vitamin D concentrations were 77 (SD 25) in the placebo group and 115 (SD 30) nmol/L in the vitamin D group. Following 5 years of intervention (median follow-up 5·7 years [IQR 5·4-6·7]), 1100 deaths were recorded (placebo 538 [5·1%]; vitamin D 562 [5·3%]). 10 661 participants in the vitamin D group and 10 649 participants in the placebo group were included in the primary analysis. Five participants (one in the vitamin D group and four in the placebo group) were not included as they requested to be withdrawn and their data to be destroyed. The HR of vitamin D3 effect on all-cause mortality was 1.04 [95% CI 0·93 to 1·18]; p=0·47)and the HR of vitamin D3 effect on cardiovascular disease mortality was 0·96 (95% CI 0·72 to 1·28; p=0·77). The HR for cancer mortality was 1·15 (95% CI 0·96 to 1·39; p=0·13) and for mortality from other causes it was 0·83 (95% CI 0·65 to 1·07; p=0·15). The odds ratio for the per-protocol analysis was OR 1·18 (95% CI 1·00 to 1·40; p=0·06). In exploratory analyses excluding the first 2 years of follow-up, those randomly assigned to receive vitamin D had a numerically higher hazard of cancer mortality than those in the placebo group (HR 1·24 [95% CI 1·01-1·54]; p=0·05). INTERPRETATION: Administering vitamin D3 monthly to unscreened older people did not reduce all-cause mortality. Point estimates and exploratory analyses excluding the early follow-up period were consistent with an increased risk of death from cancer. Pending further evidence, the precautionary principle would suggest that this dosing regimen might not be appropriate in people who are vitamin D-replete. FUNDING: The D-Health Trial is funded by National Health and Medical Research Council.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Neale RE, Baxter C, Romero BD, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol. 2022. PMID: 35026158. doi:10.1016/S2213-8587(21)00345-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。